On the stock market since 2019, it operates in the world of health and science. It has 96 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 7% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $28.3M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 36 buys and 17 sells. Management buying with its own money is usually read as a good sign.
A loss of $37.3M against $28.3M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.9 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, LOWLF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: LOWLF is a high-risk stock — not yet profitable, and its future rides on its product catching on.